???Taken together, the preclinical results presented at this conference demonstrate the potency, safety and broad activity profile of STA-9090, both as a single agent and in combination,??? said Vojo Vukovic, M.D., Ph.D., Chief Medical Officer, Synta Pharmaceuticals. ???There is a great deal of interest in the oncology community in the Hsp90 inhibitor category. Based on the strong scientific results we and others have seen with STA-9090, the superior safety and activity profile compared to first generation Hsp90 inhibitors, the limited success of first generation Hsp90 inhibitors in the clinic, and the encouraging clinical results seen to date with STA-9090, we believe STA-9090 can be the first Hsp90 inhibitor to realize the true potential of this category.???

STA-9090 is currently in four Phase 1 and Phase 1/2 trials. Synta expects to report data from these studies and initiate new trials across multiple tumor types later this year and in the first half of 2010.

Source Synta Pharmaceuticals